Empower your strategies with our Net Present Value Model: Chimerix Inc’s Dordaviprone report and make more profitable business decisions.
Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development.
Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.

Chimerix Inc’s Dordaviprone Drug Details:
Dordaviprone hydrochloride is under development for the treatment of high-grade glioma including thalamus, meningioma, hypothalamus, brainstem, cerebellum, midbrain, or spinal cord, diffuse midline glioma, neuroendocrine tumors, diffuse intrinsic pontine glioma, pheochromocytoma-paraganglioma (PC-PG) and endometrial, prostate cancers, , relapsed or refractory acute myelocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, multiple myeloma, and unspecified indication. The drug candidate is administered orally in the form of capsules. The drug candidate is developed based on cell-based molecular imaging platform. It acts by targeting JAK/STAT pathway, Akt and ERK and ClpP.It was also under development for the treatment of non-small cell lung cancer and triple-negative breast cancer. It was also under development for the treatment of relapsed/refractory non-Hodgkin’s lymphoma includes diffuse large b-cell lymphoma, mantle cell lymphoma, gliosarcoma, cutaneous T-cell lymphoma, ovarian, colorectal cancer and transformed large cell lymphoma.
Report Coverage
GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.
Scope of Report
- Drug Name
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
- Patent law
- Known and Projected regulatory approval processes
- Cash flows
- Potential applicable patients
- Drug margins
- Company expenses
- Pricing estimates
Reasons to buy
- Obtain a better understanding of the quantitative value of Net Present Value Model: Chimerix Inc’s Dordaviprone.
- Access another data source to use in the valuation of Net Present Value Model: Chimerix Inc’s Dordaviprone.
- Create or support internal NPV models to improve accuracy.
- Understand a drug’s expected profit, considering revenue and cost forecasts leveraging public and proprietary data sets.






